The Transcription Factor GLI1 Mediates TGFβ1 Driven EMT in Hepatocellular Carcinoma via a SNAI1-Dependent Mechanism

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Zheng, Xin ^a,b,c   Rumie Vittar, Natalia B ^b,c   Gai, Xiaohong ^a,b,c   Fernandez Barrena, Maite G ^b,c   Moser, Catherine D ^b,c   Hu, Chunling ^b,c   Almada, Luciana L ^b,c   McCleary Wheeler, Angela L ^b,c   Elsawa, Sherine F ^b,c,d   Vrabel, Anne M ^b,c   Shire, Abdirashid M ^b,c   Comba, Andrea ^b,c   Thorgeirsson, Snorri S ^e   Kim, Youngsoo ^f   Liu, Qingguang ^a   Fernandez Zapico, Martin E ^b,c   Roberts, Lewis R ^b,c  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC CANCER CENTER   (United States)

^d NORTHERN ILLINOIS UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR SNAI1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PHENOTYPE; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICROSCOPY, FLUORESCENCE; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PLASMIDS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84869782914     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049581     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2. Eguchi S, Kanematsu T, Arii S, Omata M, Kudo M, et al. (2011) Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinoma. Br J Surg 98: 552-557.
3. Kim SH, Choi SB, Lee JG, Kim SU, Park MS, et al. (2011) Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy. J Gastrointest Surg 15: 598-607.
4. Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, et al. (2007) Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol 33: 868-873.
5. Roessler S, Budhu A, Wang XW, (2007) Future of molecular profiling of human hepatocellular carcinoma. Future Oncol 3: 429-439.
6. Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, et al. (2000) Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg 191: 381-388.
7. Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, et al. (1999) Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 17: 324-331.
8. Lahsnig C, Mikula M, Petz M, Zulehner G, Schneller D, et al. (2009) ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogene 28: 638-650.
9. Nagai T, Arao T, Furuta K, Sakai K, Kudo K, et al. (2011) Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 10: 169-177.
10. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S, (2005) Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129: 1375-1383.
11. Zheng X, Yao Y, Xu Q, Tu K, Liu Q, (2010) Evaluation of glioma-associated oncogene 1 expression and its correlation with the expression of sonic hedgehog, E-cadherin and S100a4 in human hepatocellular carcinoma. Mol Med Report 3: 965-970.
12. van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, et al. (2009) Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol 5: 1169-1179.
13. Reichl P, Haider C, Grubinger M, Mikulits W, (2012) TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma. Curr Pharm Des [Epub ahead of print].
14. Talbot LJ, Bhattacharya SD, Kuo PC, (2012) Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol 3 (2) (): 117-36.
15. Leopold PL, Vincent J, Wang H, (2012) A comparison of epithelial-to-mesenchymal transition and re-epithelialization. Semin Cancer Biol [Epub ahead of print].
16. Li X, Deng W, Nail CD, Bailey SK, Kraus MH, et al. (2006) Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene 25 (4) (): 609-21.
17. Colvin Wanshura LE, Galvin KE, Ye H, Fernandez-Zapico ME, Wetmore C, (2011) Sequential activation of Snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells. Cancer Res 71 (15) (): 5336-45.
18. Xu Z, Shen MX, Ma DZ, Wang LY, Zha XL, (2003) TGF-beta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. Cell Res 13: 343-350.
19. Sun VC, Sarna L, (2008) Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs 12: 759-766.
20. Yang JD, Harmsen WS, Slettedahl SW, Enders FT, Therneau TM, et al. (2011) Factors that Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance. Clinical Gastroenterology and Hepatology 9: 617-623.
21. Chung KY, Cheng IK, Ching AK, Chu JH, Lai PB, et al. (2011) Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition. Hepatology 54: 307-318.
22. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, et al. (2006) Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 12: 5369-5376.
23. Severi T, van Malenstein H, Verslype C, van Pelt JF, (2010) Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 31: 1409-1420.
24. Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM, et al. (2011) Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition. PLoS One 6: e18878.
25. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, et al. (2009) Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med 1: 338-351.
26. Blobe GC, Schiemann WP, Lodish HF, (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358.
27. Pakala SB, Singh K, Reddy SD, Ohshiro K, Li DQ, et al. (2011) TGF-beta1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene 30: 2230-2241.
28. Zhang HJ, Wang HY, Zhang HT, Su JM, Zhu J, et al. (2011) Transforming growth factor-beta1 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition. Mol Cell Biochem 355: 309-314.
29. Rahimi RA, Leof EB, (2007) TGF-beta signaling: a tale of two responses. J Cell Biochem 102: 593-608.
30. Schiemann WP, (2007) Targeted TGF-beta chemotherapies: friend or foe in treating human malignancies? Expert Rev Anticancer Ther 7: 609-611.
31. Tian M, Schiemann WP, (2009) The TGF-beta paradox in human cancer: an update. Future Oncol 5: 259-271.
32. Wu J, Ru NY, Zhang Y, Li Y, Wei D, et al. (2011) HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-beta signaling and is transcriptionally regulated by Slug. Oncogene.
33. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83.
34. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y, (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15: 195-206.
35. Fiaschi M, Kolterud A, Nilsson M, Toftgård R, Rozell B, (2011) Targeted expression of GLI1 in the salivary glands results in an altered differentiation program and hyperplasia. Am J Pathol 179 (5) (): 2569-79.
36. Kuphal S, Shaw-Hallgren G, Eberl M, Karrer S, Aberger F, et al. (2011) GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma. Oncogene 30 (44) (): 4523-30.
37. Li X, Deng W, Lobo-Ruppert SM, Ruppert JM, (2007) Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. Oncogene 26 (31) (): 4489-98.
38. Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, et al. (2007) Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 67: 3583-3593.
39. Sasaki H, Hui C, Nakafuku M, Kondoh H, (1997) A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development 124: 1313-1322.
40. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, et al. (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12: 410-416.